PDS BIOTECHNOLOGY CORP
PDS Biotechnology Corporation (PDSB) is a small‑cap, clinical‑stage biotechnology company focused on developing immunotherapies and vaccine candidates that aim to harness the immune system against disease. With a market capitalisation of roughly $45.2m, the company remains early‑stage: its value is strongly linked to clinical trial outcomes, regulatory milestones and partner or funding developments. Investors should be aware of the sector’s typical risks — long development timelines, the potential for trial setbacks, regulatory uncertainty, limited revenues and possible share dilution from fundraising. That combination can create pronounced share price volatility. This summary is for educational purposes only and not personal financial advice. It may suit investors who understand high‑risk, long‑horizon biotech propositions; it is not appropriate for those seeking stable income or short‑term gains. Always review up‑to‑date filings, clinical results and consult an authorised financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying PDS Biotechnology's stock with a target price of $11.50, indicating significant growth potential.
Financial Health
PDS Biotechnology Corp shows moderate financial performance with steady cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PDSB
The Plasma Profit Pipeline
Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.
Published: August 19, 2025
Explore BasketThe Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketPharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketNext-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical‑stage pipeline
Pipeline milestones and trial readouts can drive share movements; however, clinical outcomes are uncertain and timelines can be long.
Proprietary technology
A focus on delivery approaches and immune activation may differentiate the company, though technical and commercial execution remain key risks.
Small‑cap dynamics
With a modest market capitalisation, shares can be volatile and additional fundraising may be needed, which could dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
